Breaking the Barrier: Unraveling the No‐Reflow Phenomenon in Cardiovascular Medicine
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Stephanie Howes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: No-Reflow Phenomenon, Coronary Circulation, Microcirculation, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI). With incidence rates reaching 11.5% in AMI‐related percutaneous coronary interventions (PCI), no‐reflow is a major contributor to poor cardiac outcomes, including heart failure and increased mortality. At its core, no‐reflow stems from microvascular obstruction (MVO), driven by endothelial dysfunction, distal embolization, and reperfusion‐related injury. Capillaries become clogged, inflammation surges, and oxidative stress wreaks havoc, leading to irreversible tissue damage. Advanced imaging techniques like cardiac magnetic resonance (CMR) and myocardial contrast echocardiography (MCE) now allow for more precise detection, offering hope for earlier intervention. Despite decades of research, effective treatments remain elusive. Conventional strategies, from vasodilators to mechanical interventions, often fall short. However, emerging therapies like Nicorandil, a potassium‐channel activator with nitrate properties, show promise in improving microvascular perfusion and reducing inflammation. To break the barrier of no‐reflow, a paradigm shift is needed: one that integrates cutting‐edge diagnostics, personalized medicine, and innovative pharmacological and mechanical interventions. As we unravel the complexities of this phenomenon, the future holds the potential to transform outcomes for patients battling myocardial ischemia‐reperfusion injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, USA.
- University of Texas Health Science Center, San Antonio, Texas, USA.
- Audie L. Murphy VA, San Antonio, Texas, USA.
ORCID-Profile: Stephanie Howes, Loreto Calaquian, Robert Chilton
Zitieren
APA
Howes, S., Altaee, O., Ramirez, A., Calaquian, L., Asif, A., Stone, C., Hammadah, M., Roy, D., Ramsey, B., & Chilton, R. (2025). Breaking the Barrier: Unraveling the No‐Reflow Phenomenon in Cardiovascular Medicine. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70017
Vancouver
Howes S, Altaee O, Ramirez A, Calaquian L, Asif A, Stone C, et al. Breaking the Barrier: Unraveling the No‐Reflow Phenomenon in Cardiovascular Medicine. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70017
BibTeX
@article{Howes2025,
author = {Howes, Stephanie and Altaee, Osamah and Ramirez, Ariana and Calaquian, Loreto and Asif, Anum and Stone, Collin and Hammadah, Muhammad and Roy, Debanshu and Ramsey, Bryan and Chilton, Robert},
title = {Breaking the Barrier: Unraveling the No‐Reflow Phenomenon in Cardiovascular Medicine},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70017}
}
EUVIMED